1. Home
  2. AVTX vs GLU Comparison

AVTX vs GLU Comparison

Compare AVTX & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVTX
  • GLU
  • Stock Information
  • Founded
  • AVTX 2011
  • GLU 2004
  • Country
  • AVTX United States
  • GLU United States
  • Employees
  • AVTX N/A
  • GLU N/A
  • Industry
  • AVTX Biotechnology: Pharmaceutical Preparations
  • GLU Finance/Investors Services
  • Sector
  • AVTX Health Care
  • GLU Finance
  • Exchange
  • AVTX Nasdaq
  • GLU Nasdaq
  • Market Cap
  • AVTX 88.4M
  • GLU 92.2M
  • IPO Year
  • AVTX 2015
  • GLU N/A
  • Fundamental
  • Price
  • AVTX $8.18
  • GLU $15.56
  • Analyst Decision
  • AVTX Strong Buy
  • GLU
  • Analyst Count
  • AVTX 4
  • GLU 0
  • Target Price
  • AVTX $33.00
  • GLU N/A
  • AVG Volume (30 Days)
  • AVTX 64.7K
  • GLU 12.4K
  • Earning Date
  • AVTX 03-28-2025
  • GLU 01-01-0001
  • Dividend Yield
  • AVTX N/A
  • GLU 8.60%
  • EPS Growth
  • AVTX N/A
  • GLU N/A
  • EPS
  • AVTX N/A
  • GLU 0.62
  • Revenue
  • AVTX $820,000.00
  • GLU N/A
  • Revenue This Year
  • AVTX N/A
  • GLU N/A
  • Revenue Next Year
  • AVTX N/A
  • GLU N/A
  • P/E Ratio
  • AVTX N/A
  • GLU $22.50
  • Revenue Growth
  • AVTX N/A
  • GLU N/A
  • 52 Week Low
  • AVTX $4.18
  • GLU $11.61
  • 52 Week High
  • AVTX $34.46
  • GLU $15.40
  • Technical
  • Relative Strength Index (RSI)
  • AVTX 52.50
  • GLU 57.11
  • Support Level
  • AVTX $7.82
  • GLU $15.40
  • Resistance Level
  • AVTX $8.50
  • GLU $15.68
  • Average True Range (ATR)
  • AVTX 0.78
  • GLU 0.31
  • MACD
  • AVTX 0.20
  • GLU 0.10
  • Stochastic Oscillator
  • AVTX 73.11
  • GLU 86.79

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

Share on Social Networks: